tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Enliven Therapeutics’ Promising CML Study: A Potential Game-Changer?
PremiumCompany AnnouncementsEnliven Therapeutics’ Promising CML Study: A Potential Game-Changer?
23d ago
Enliven Therapeutics Advances in HER2 Mutant Lung Cancer Study
Premium
Company Announcements
Enliven Therapeutics Advances in HER2 Mutant Lung Cancer Study
23d ago
Enliven Therapeutics Appoints New Directors at Annual Meeting
Premium
Company Announcements
Enliven Therapeutics Appoints New Directors at Annual Meeting
28d ago
Optimistic Buy Rating for Enliven Therapeutics Driven by Promising ELVN-001 Data and Strategic Growth Plans
PremiumRatingsOptimistic Buy Rating for Enliven Therapeutics Driven by Promising ELVN-001 Data and Strategic Growth Plans
1M ago
Enliven assigned with a Buy at Goldman Sachs
Premium
The Fly
Enliven assigned with a Buy at Goldman Sachs
1M ago
Enliven Therapeutics: Promising Phase 1 Data and Strong Financial Position Support Buy Rating
Premium
Ratings
Enliven Therapeutics: Promising Phase 1 Data and Strong Financial Position Support Buy Rating
1M ago
Enliven Therapeutics’ ELVN-001: Promising CML Treatment with Strong Safety Profile and Upcoming Phase 1b Trial Insights
PremiumRatingsEnliven Therapeutics’ ELVN-001: Promising CML Treatment with Strong Safety Profile and Upcoming Phase 1b Trial Insights
1M ago
Enliven Therapeutics: Buy Rating Backed by Promising ELVN-001 Developments in CML Treatment
Premium
Ratings
Enliven Therapeutics: Buy Rating Backed by Promising ELVN-001 Developments in CML Treatment
2M ago
Promising Potential of Enliven Therapeutics’ ELVN-001 Drives Buy Rating
Premium
Ratings
Promising Potential of Enliven Therapeutics’ ELVN-001 Drives Buy Rating
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100